Directed new share issue in BerGenBio ASA (NO) — NOK 74 million

Carnegie acted as joint bookrunner in the directed new share issue of 5,495,144 new shares at a subscription price of NOK 13.50 per share. BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. June 2019.